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Introduction: The aim of this study was to explore the impact of augmented creatinine clearance and differing
minimum inhibitory concentrations (MIC) on piperacillin pharmacokinetic/pharmacodynamic (PK/PD) target
attainment (time above MIC (fT>MIC)) in critically ill patients with sepsis receiving intermittent dosing.
Methods: To be eligible for enrolment, critically ill patients with sepsis had to be receiving piperacillin-tazobactam 4.5 g
intravenously (IV) by intermittent infusion every 6 hours for presumed or confirmed nosocomial infection without
significant renal impairment (defined by a plasma creatinine concentration greater than 171 μmol/L or the need
for renal replacement therapy). Over a single dosing interval, blood samples were drawn to determine unbound
plasma piperacillin concentrations. Renal function was assessed by measuring creatinine clearance (CLCR). A population
PK model was constructed, and the probability of target attainment (PTA) for 50% and 100% fT>MIC was calculated for
varying MIC and CLCR values.
Results: In total, 48 patients provided data. Increasing CLCR values were associated with lower trough plasma piperacillin
concentrations (P < 0.01), such that with an MIC of 16 mg/L, 100% fT>MIC would be achieved in only one-third (n = 16) of
patients. Mean piperacillin clearance was approximately 1.5-fold higher than in healthy volunteers and correlated with
CLCR (r = 0.58, P < 0.01). A reduced PTA for all MIC values, when targeting either 50% or 100% fT>MIC, was noted with
increasing CLCR measures.
Conclusions: Standard intermittent piperacillin-tazobactam dosing is unlikely to achieve optimal piperacillin exposures
in a significant proportion of critically ill patients with sepsis, owing to elevated drug clearance. These data suggest that
CLCR can be employed as a useful tool to determine whether piperacillin PK/PD target attainment is likely with a range
of MIC values.Introduction
Effective antibacterial therapy is crucial for improving
outcomes for patients with sepsis [1]. Current inter-
national guidelines stress the importance of early admin-
istration of broad-spectrum agents [2], with the caveat
that significant dose adjustment may be required in pa-
tients who are critically ill. This is a reflection of the
unique physiology often encountered in these patients
[3], which may dramatically distort pharmacokinetics
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scribed in the literature [4]. They lead to poorly predict-
able and often subtherapeutic plasma concentrations [5].
The minimum antibacterial exposure required in clinical
practice to maximize bacterial killing and optimize clinical
outcomes remains controversial. For β-lactams, preclinical
studies support maintaining prolonged free drug concen-
trations above the minimum inhibitory concentration
(MIC) of the likely pathogen [6]. In vivo animal data indi-
cate that this period should be at least 40% to 70% of the
dosing interval (40% to 70% fT>MIC) [7], although various
retrospective clinical evaluations have recommended
more aggressive targets, such as 100% fT>MIC [8] and
trough concentration to MIC ratios (Cmin:MIC) >5 [9].is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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lence study of antibacterial concentrations in critical
illness, researchers demonstrated that clinical failure is
three times more likely when β-lactam exposure is less
than 50% fT>MIC [5] and that increasing exposures are
associated with an increased likelihood of clinical cure.
Whereas these data demonstrate why achievement of
target drug exposures is important, they do not robustly
define which patients are at risk of subtherapeutic dos-
ing. Clinicians commonly consider the likely pathogen,
its susceptibility profile and the potential for drug tox-
icity when selecting an empirical dosing regimen. An as-
sessment of renal function is common, with evidence of
acute or chronic renal impairment often triggering dose
reduction to avoid drug accumulation. For β-lactams,
the converse—dose escalation in the setting of aug-
mented renal function—has been infrequently reported
in clinical practice.
Previously published data, however, suggest that patients
with augmented renal clearance (ARC), which often mani-
fests as an elevated urinary creatinine clearance (CLCR),
are at particular risk of subtherapeutic β-lactam concen-
trations [10,11]. This, therefore, represents an attractive
measure to guide dose selection, although few data are
available that integrate CLCR, pathogen susceptibility and
drug exposures. As such, the aim of this analysis was to
explore the impact of elevated CLCR and different patho-
gen susceptibilities, on piperacillin pharmacokinetic/phar-
macodynamic (PK/PD) target attainment in critically ill
patients receiving intermittent dosing.
Material and methods
Setting
This single-centre observational study was undertaken
in a tertiary level, university-affiliated intensive care unit
(ICU). Ethical approval was obtained from the Royal
Brisbane and Women’s Hospital Human Research Ethics
Committee (HREC 2007/188), with written informed
consent obtained from either the patient or the pa-
tient’s nominated substitute decision-maker.
Study population
Patients were eligible for enrolment if they were between
18 and 80 years of age and were receiving piperacillin-
tazobactam for the treatment of sepsis (defined as
presumed or confirmed nosocomial infection while
manifesting a systemic inflammatory response syndrome
[12]). Patients were excluded if they (1) did not have an
intraarterial line inserted as part of routine management
(to allow repeated plasma sampling without additional
venipuncture), (2) had renal impairment (defined by a
plasma creatinine concentration (CR) greater than 171
μmol/L or the need for renal replacement therapy) or (3)
had a history of allergy to piperacillin or iodine. This,therefore, represents a convenience sample of critically ill
septic patients admitted to our institution without signifi-
cant renal impairment.
Study protocol
The protocol pertaining to this study has been published
in detail elsewhere [13]. In brief, 4.5 g of piperacillin-
tazobactam (Tazocin EF; Pfizer Australia Pty Ltd, West
Ryde, NSW, Australia) diluted in 50 ml of 0.9% sodium
chloride was administered over 20 minutes as part of the
patient’s prescribed course of therapy. Blood samples to
determine plasma piperacillin concentrations were drawn
predose and at 20 minutes (end of infusion), 40 minutes,
60 minutes, 210 minutes and 360 minutes. All urine sam-
ples were collected via an indwelling urinary catheter over
the dosing interval, following which urine volume and
urinary CR concentration were determined by laboratory
analysis. Plasma CR concentrations on the day of investi-
gation were used to calculate CLCR. No specific CLCR
value was used to define renal impairment or ARC, as our
aim was to use these measures as continuous variables in
analysis.
Additional data, including the requirement for mechan-
ical ventilation, vasopressor support, modified Sequential
Organ Failure Assessment (SOFA) score (excluding the
neurological component) and 24-hour fluid balance, were
documented on the day of drug administration. Admis-
sion Acute Physiology and Chronic Health Evaluation
(APACHE) II score, body mass index (BMI) and ICU and
in-hospital mortality were also recorded.
Sample handling, storage and measurement
Blood samples were immediately placed on ice and centri-
fuged within 60 minutes at 3,000 rpm for 10 minutes.
Plasma samples were then stored at −80°C until analysis.
An ultraviolet high-performance liquid chromatography
(HPLC-UV) assay was used to measure piperacillin con-
centrations in plasma. All bioanalytical techniques were
validated and conducted in accordance with the criteria of
the US Food and Drug Administration’s guidance for in-
dustry on bioanalysis [14]. To isolate the unbound fraction
for analysis, protein-bound piperacillin was removed from
the plasma sample with centrifugal filter devices (Centri-
free 30,000 NMWL; Merck Millipore, Tullagreen, Ireland).
The lower limit of quantification for unbound piperacillin
concentrations was 1 mg/L.
Plasma concentration data
The final (360 minutes) plasma sample was taken as the
trough unbound piperacillin concentration (Cmin). These
samples were then compared to an MIC of 16 mg/L to
determine whether 100% fT>MIC would have been
achieved. This represents the highest MIC for susceptible
bacteria (for example, the Pseudomonas aeruginosa MIC
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European Committee on Antimicrobial Susceptibility
Testing (EUCAST) [15]. We chose to assess the ad-
equacy of dosing in terms of this ‘worst-case scenario’,
as MIC data are often not initially available to the clin-
ician. The 100% fT>MIC target was utilized in this ana-
lysis, as more aggressive drug exposures have been
demonstrated to improve both microbiological and
clinical outcomes [5,8,9].
Population pharmacokinetics modelling
Concentration-time data were analysed using nonlinear
mixed-effects modelling (NONMEM version 7.1; GloboMax,
Ellicott City, MD, USA). A Digital Fortran compiler was
used, and the runs were executed using Wings for NON-
MEM [16]. The first-order conditional estimation method
with interaction was used throughout model building.
Unbound plasma piperacillin concentrations were fit-
ted to one-, two- or three-compartment linear models
using subroutines from the NONMEM library. Between-
subject variability (BSV) was evaluated using an exponential
variability model. Various models for residual unexplained
variability (RUV) were also tested.
Pharmacokinetics model diagnostics
Visual inspection of diagnostic scatter plots and the
NONMEM objective function value (OFV) were used to
evaluate goodness of fit. Statistical comparison of nested
models was undertaken in the NONMEM program
using log-likelihood ratios, which are assumed to be
χ2-distributed. On the basis of a χ2 test of the difference
in OFV, a decrease in the OFV of 3.84 units (P < 0.05) for
1 degree of freedom was considered statistically signifi-
cant. Decreases in BSV of one of the parameters of at least
10% were also accepted for inclusion in a more compli-
cated model.
Population pharmacokinetics bootstrap
A nonparametric bootstrap method (n = 1,000) was used
to study the uncertainty of the pharmacokinetic param-
eter estimates in the final model. From the bootstrap
empirical posterior distribution, we were able to obtain
the 95% confidence interval (2.5% to 97.5% percentiles)
for the parameters, as described previously [17].
Probability of target attainment
Monte Carlo simulations performed in NONMEM were
employed to determine the probability of target attain-
ment (PTA) with varying MIC (2 to 64 mg/L) and CLCR
(10 to 300 ml/min in 10-ml/min increments) values
using a standard 4.5-g piperacillin-tazobactam dose ad-
ministered every 6 hours as an intermittent 20-minute
infusion. The PTAs for achieving 50% fT>MIC and 100%
fT>MIC with piperacillin were calculated.Cumulative fraction of response
The cumulative fraction of response (CFR) determines
the likely success of treatment by comparing the phar-
macodynamic exposure (PTA) against the MIC distribu-
tion of a specific population of microorganisms [18].
The wild-type MIC distribution for Pseudomonas aerugi-
nosa against piperacillin was obtained from the EUCAST
database [15]. The CFR was calculated for both 50%
fT>MIC and 100% fT>MIC by using a range of CLCR
values. Dosing was a priori considered successful if the
CFR was at least 80%.
Statistical analysis
Continuous data are presented as the mean (standard de-
viation) or median (interquartile range). Categorical data
are presented as counts (%). Correlation was assessed by
means of a scatter graph and Pearson correlation coeffi-
cient (r). For comparisons between groups, we used an
independent Student’s t-test, Mann–Whitney U test, or
one-way analysis of variance for continuous data, as
well as a χ2 or Fisher’s exact test for categorical data,
where analysis assumptions were met. A P-value <0.05
was considered statistically significant, and all analyses
were performed using SPSS version 21 software (IBM
SPSS, Chicago, IL, USA).
Results
Demographic data
Forty-eight patients were included in the analysis. All pa-
tients were receiving 4.5 g of piperacillin-tazobactam by
intermittent IV infusion over 20 minutes every 6 hours for
treatment of presumed or confirmed nosocomial infec-
tion. Demographic, admission, anthropometric, illness se-
verity and outcome data are presented in Table 1.
Sampling occurred after a median of 9 (4 to 13) doses
and, on average, 5.2 (3.7) days postadmission to the ICU.
Half of the patients were receiving piperacillin-tazobactam
for treatment of nosocomial pneumonia. The cohort was
relatively young and overweight with moderate to se-
vere illness severity. The vast majority required invasive
mechanical ventilation (>90%), whereas only one-fourth
needed vasopressor support. As per the inclusion criteria,
plasma CR concentrations were relatively low (79.5 (31.4)
μmol/L). The mean CLCR over the study period was 122
(59.2) ml/min, although there was significant variability
between patients: 15 patients had a CLCR <90 ml/min, 22
had a CLCR >130 ml/min and 16 had a CLCR >150 ml/min.
Plasma concentration data
In 11 patients, the Cmin value was either below the lower
limit of detection (n = 10) or not available (n = 1). Using
an MIC of 16 mg/L, piperacillin intermittent infusion
would achieve 100% fT>MIC (Cmin >16 mg/L) in only 16
(34.0%) of 47 patients. Older age (P = 0.01), higher
Table 1 Demographic, anthropometric, illness severity
and outcome dataa
Variable N = 48
Age, yr 47.3 (17.9)
Male sex, n (%) 27 (56.3)
Height, m 1.70 (0.11)
Weight, kg 88.4 (24.2)
BMI, kg/m2 30.7 (8.78)
BSA, m2 1.98 (0.26)
Admission category/system, n (%)





Primary bacteraemia 1 (7.7)
Oncology 1 (7.7)













APACHE II score 19.4 (6.79)
Modified SOFA score, median (IQR) 3.5 (2 to 6)
Mechanical ventilation, n (%) 45 (93.8)
Use of vasopressors, n (%) 12 (25.0)
Presumed/confirmed site of infection, n (%)
Intraabdominal 14 (29.2)
Skin/soft tissue 5 (10.4)
Respiratory 24 (50.0)
Urinary 1 (2.1)
Primary bacteraemia 1 (2.1)
Unknown 3 (6.3)
24-hr fluid balance, ml 553 (1836)
Plasma CR, μmol/L 79.5 (31.4)
Measured CLCR, ml/min 122 (59.2)
ICU length of stay, days 18.2 (11.5)
ICU mortality, n (%) 4 (8.3)
Hospital mortality, n (%) 5 (10.4)
aAPACHE, Acute Physiology and Chronic Health Evaluation; BMI, Body mass index;
BSA, Body surface area; CLCR, Creatinine clearance; CR, Creatinine; ICU, Intensive
care unit; IQR, Interquartile range; SD, Standard deviation; SOFA, Sequential
Organ Failure Assessment. Data presented are mean (SD) unless otherwise stated.
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greater positive 24-hour fluid balance (P = 0.04) and more
frequent application of vasopressor therapy (P = 0.01)
were characteristics of patients likely to have higher Cmin
values, and therefore achieve this PK/PD target. No statis-
tically significant differences were noted in BMI, APACHE
II scores or the need for mechanical ventilation. Unbound
plasma piperacillin concentration time profiles grouped by
CLCR quartile are presented in Figure 1. Higher CLCR was
significantly associated with lower unbound trough
plasma piperacillin concentration (P < 0.01).
Pharmacokinetic model building
The time course of unbound plasma piperacillin concen-
trations was best described by a two-compartment linear
model with combined residual error and BSV on the vol-
ume of the central (Vc) and peripheral compartments
(Vp), drug clearance (CL) and an infusion lag descriptor
(ALAG; defined as the time taken for the residual
drug to get through the IV line after completion of
the 20-minute infusion, which was included as zero
order input). The only covariate that improved the fit
of the model was, for piperacillin CL, CLCR normal-
ized to 100 ml/min, which decreased the OFV by
18.62 (P < 0.01). In the final model, this was described
as follows:
TVCL ¼ CL  CLCR=100;
where TVCL is the typical value of piperacillin CL. The
mean parameter estimates from the final covariate
model, as well as the 95% confidence intervals from allFigure 1 Piperacillin concentrations over time grouped
according to creatinine clearance quartile. Mean piperacillin
concentration (log10 scale) and time grouped according to
creatinine clearance (CLCR) quartile: <68 ml/min (black diamonds),
68 to 114 ml/min (grey diamonds), 115 to 170 ml/min (black
squares) and >170 ml/min (grey squares). The dotted line at 16 mg/L
represents minimum inhibitory concentration.
Figure 2 Piperacillin drug clearance compared with creatinine
clearance. Scatter plot of piperacillin clearance (CL) and creatinine
clearance (CLCR). A linear regression line (solid) with 95% confidence
interval (dashed line) has been fitted to the data points (r= 0.58, P< 0.001).
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distribution (Vd) was calculated as the sum of Vc and
Vp. The goodness-of-fit plots were acceptable with an
r-value of 0.95 for the observed versus individual pre-
dicted concentrations.
Those patients who would fail to achieve 100% fT>MIC
(16 mg/L) had higher drug CL (P < 0.01) and no statisti-
cally significant difference in piperacillin Vd (P = 0.647).
As demonstrated in Figure 2, a moderate correlation was
noted between CLCR and piperacillin CL overall (r = 0.58,
P < 0.01). The PTAs for 50% fT>MIC and 100% fT>MIC with
varying MIC and CLCR values are presented in Figure 3.
The CFR for piperacillin over a range of CLCR values
using the EUCAST MIC distribution for Pseudomonas
aeruginosa is presented in Table 3.
Discussion
In this clinical analysis, we sought to explore the impact
of elevated CLCR and different susceptibilities of bacteria
on piperacillin PK/PD target attainment when adminis-
tered by intermittent infusion in a large cohort of critic-
ally ill patients with sepsis. With a MIC at the upper
limit of the susceptible range for piperacillin (16 mg/L),
only about one-third of patients would achieve 100%
fT>MIC. The primary mechanism underlying this observa-
tion appears to be significantly elevated drug CL in paral-
lel with higher CLCR in some patients. This phenomenonTable 2 Mean parameter estimates and bootstrap mean
(95% confidence interval) estimates for the final population
pharmacokinetic modela
Parameter Model Bootstrap
Mean Mean 95% confidence interval
2.5% 97.5%
Fixed effects
CL (L/hr) 16.3 16.2 14.0 18.9
Vc (L) 19.9 15.9 0.7 27.8
Vp (L) 18.8 21.3 11.1 32.3
Q (L/h) 37.3 42.9 22.0 73.3
ALAG (hr) 0.8 0.13 0.01 0.31
Random effects BSV (% CV)
CL (L/hr) 56.0 55.3 45.2 65.4
Vc (L) 29.6 23.5 0.2 45.7
Vp (L) 67.6 69.2 24.6 158.4
ALAG (hr) 0.3 0.4 0.05 0.8
Random error
RUV (% CV) 1.0 1.3 0.3 3.1
RUV (SD, mg/L) 0.3 0.3 0.2 0.4
aALAG, Infusion lag time; BSV, Between-subject variability; CL, Clearance; CV,
Coefficient of variation; Q, Intercompartmental clearance; RUV, Residual
unexplained variability; SD, Standard deviation; Vc, Volume of the central
compartment; Vp, Volume of the peripheral compartment.of augmented renal clearance [19,20] is being described in
critically ill patients with increasing frequency [21,22],
which suggests that clinicians should be wary of conven-
tional dosing in this setting. Indeed, the CFR suggests that
only with lower CLCR values (<90 ml/min) will an ad-
equate fraction of Pseudomonas aeruginosa isolates be
suitably covered with this dosing regimen.
Pharmacokinetic modelling for the study cohort re-
vealed a mean piperacillin CL of approximately 1.5-fold
that reported in healthy volunteers [23]. Similar derange-
ment in piperacillin CL has been reported in previous
studies of critically ill patients [24,25], highlighting the
unique PK observed in this setting [4]. Of note, pipera-
cillin Vd was also significantly larger overall. Changes in
Vd have been observed with other β-lactams in critical
illness [26] and likely reflect the substantial fluid shifts
frequently encountered [27]. Use of unbound piperacillin
concentrations in the PK model may also have contrib-
uted to the higher Vd observed, although use of free
concentrations is essential to describe the pharmaco-
logically active fraction of piperacillin.
The specific mechanisms underlying ARC in critically
ill patients remain uncertain. Researchers have recently
identified a modest correlation between cardiac index
and CLCR in patients with sepsis [28], suggesting that in-
creased renal perfusion and solute delivery may be a key
factor. Younger age and lower illness severity scores
have previously been identified as risk factors for ARC
[28,29], which is further demonstrated by our study data.
Work by Shimamoto et al. highlights the role of sys-
temic inflammation, with an increasing number of sys-
temic inflammatory response syndrome criteria being
strongly correlated with higher drug clearance and lower
plasma concentrations in nonventilated patients receiv-
ing vancomycin [30]. Together, these findings imply an
important interaction between systemic inflammation
Table 3 Cumulative fraction of response for piperacillin
over a range of creatinine clearance valuesa












a50% fT>MIC, 50% time above the minimum inhibitory concentration; 100%
fT>MIC, 100% time above the minimum inhibitory concentration; CFR,
Cumulative fraction of response; CLCR, Creatinine clearance. Data represent the
CFR when targeting 50% fT>MIC and 100% fT>MIC with a range of CLCR values
following a 4.5 g piperacillin-tazobactam dose administered every 6 hours as
an intermittent 20 minute infusion. The wild-type MIC distrubiton of
Pseudomonas aeruginosa has been employed. Boldface represents those CLCR
values where target exposures would be achieved in at least 80% of isolates.
Figure 3 Probability of target attainment with varying
creatinine clearance. Graphs depict the probability (%) of attaining
50% (A) and 100% (B) time above the minimum inhibitory
concentration (fT>MIC) following a 4.5 g piperacillin-tazobactam dose
administered every 6 hours as an intermittent 20-minute infusion,
and CLCR values. Varying minimum inhibitory concentrations (MIC)
are displayed: 2 mg/L (black diamonds), 4 mg/L (grey diamonds),
8 mg/L (black squares), 16 mg/L (grey squares), 32 mg/L (black
circles), and 64 mg/L (grey circles).
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neglected in antibacterial dosing regimens [31]. As such,
the characteristics of patients included in this study
(younger age, admission posttrauma and less organ dys-
function) are useful in defining scenarios where a mea-
sured CLCR or therapeutic drug monitoring should be
employed to determine the need for higher than stand-
ard piperacillin dosing.
The prevalence of ARC varies significantly, depending
upon the definition employed and institutional case mix
[32-35]. In a recent multicentre study of CLCR in critically ill
patients with ‘normal’ plasma CR concentrations, researchers
identified an incidence of ARC (CLCR ≥130 ml/min/1.73 m
2)
of approximately 65% in the first 7 days in the ICU [36].Importantly, patients who manifested ARC on day 1 were
significantly more likely to do so on subsequent measures,
indicating that augmented drug CL is unlikely to be short-
lived. A lower incidence (about 52%) of ARC was observed
in a mixed cohort of critically ill patients receiving antibac-
terial therapy, although an association with greater thera-
peutic failure was demonstrated [29].
Other investigators have highlighted the importance of
renal function in informing β-lactam dosing. Patel and
colleagues examined piperacillin PK data from 105 hos-
pitalized patients to determine optimal intermittent and
extended-infusion dosing in those with renal impairment
[37]. Of interest, with an estimated CLCR of 100 ml/min
and a traditional regimen of 4.5 g administered IV every
6 hours, the probability of target attainment (50%
fT>MIC) decreased sharply (<80%) with MIC values
greater than 4 mg/L [34]. With our data, we identified
higher CLCR thresholds (Figure 3), although this likely
reflects differences in case mix and the use of measured
rather than estimated CLCR. Importantly, previous data
reinforce the significant disparity between calculated and
measured CLCR in patients manifesting ARC [38,39].
More recently, Carlier et al. examined meropenem
and piperacillin-tazobactam target attainment in a co-
hort of critically ill patients receiving extended-infusion
dosing. In those patients manifesting ARC (CLCR ≥130
ml/min), the probability of achieving either 50% fT>MIC
or 100% fT>MIC was significantly reduced [40]. Regres-
sion analysis also identified CLCR as the only significant
predictor of target attainment, a finding also demonstrated
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in obese, non-critically ill patients [41]. Our data compare
favourably with these studies, although the current ana-
lysis involves a wider range of MIC values, highlighting
the impact of variable bacterial susceptibility. Pea and
colleagues similarly examined meropenem continuous
infusion dosing in critically ill patients with severe
Gram-negative infection [42]. Dosing nomograms to
achieve specific steady-state concentrations were de-
veloped with a linear relationship between dose and es-
timated CLCR [42].
Changing bacterial susceptibility represents a global
challenge in medical practice. Our analyses highlight the
importance of the MIC as the denominator in the PK/
PD relationship in determining adequate antibacterial
dosing. Less susceptible pathogens are more common
in the ICU [43], and significant regional variation in
resistance patterns also exists [44]. In two large antibac-
terial susceptibility prevalence studies, MIC90 values for
piperacillin-tazobactam against Pseudomonas aeruginosa
were reported at or above 64 mg/L [45,46]. Our data sug-
gest that achieving 50% fT>MIC in such a scenario is un-
likely with conventional piperacillin intermittent dosing
and reinforce the use of a much lower susceptibility break-
point (16 mg/L) with this dosing strategy. However, even
in this circumstance, an elevated CLCR will significantly
reduce the probability of target attainment, as demon-
strated in Figure 3. In contrast, where a highly susceptible
pathogen is identified and piperacillin is used as directed
therapy, standard doses may still be sufficient, even with
extremely high CLCR values. Importantly, this underlines
the significance of such microbiological susceptibility data
in accurate clinical decision-making.
Our study has several limitations. The data were drawn
from a single centre and as such may not be representative
of case mix at other institutions. Our inclusion criteria
were designed to select a cohort of patients without sig-
nificant renal impairment, as effective antibacterial dosing
in this group is less likely with standard dosing. As such,
ARC is likely to have been more common in our study co-
hort than in a broader ICU population. However, our rela-
tively high plasma CR cutoff allowed us to explore renal
function (as determined by CLCR) as a covariate in PK
modelling. We did not include tazobactam PK, because it
is not active against Pseudomonas aeruginosa, although,
as it is renally eliminated, increased drug CL is also
likely in ARC. We examined the likelihood of target at-
tainment using varying susceptibility levels rather than
clinical MIC data. This improves generalizability for
empiric dosing, although it limits conclusions about
the adequacy of drug exposure in any specific patient.
Furthermore, given the small sample size, we are un-
able to make any firm conclusions about the clinical
implications of these analyses.Conclusions
Our results indicate that an empiric intermittent infu-
sion of 4.5 g of piperacillin-tazobactam is unlikely to
achieve optimal piperacillin exposure in a significant
proportion of critically ill patients with sepsis, particu-
larly when targeting less susceptible pathogens. This ap-
pears to be driven primarily by an increase in drug CL
in some patients, and our data reinforce the value of
CLCR in predicting whether optimal exposures are likely.
As such, clinicians should be wary of the adequacy of
conventional dosing in patients manifesting ARC, and
research should now be focused on the use of novel ad-
ministration strategies in such patients, in addition to
correlating changes in antibacterial PK with clinical
outcomes.
Key messages
 Elevated CLCR in septic critically ill patients is
associated with higher piperacillin CL, a concept
referred to as augmented renal clearance, or ARC.
 When employing intermittent administration, this
will result in suboptimal plasma concentrations for
significant periods of the dosing interval.
 Increasing CLCR reduces the probability of target
attainment (fT>MIC), particularly with more resistant
organisms.
 When considering the MIC distribution of
Pseudomonas aeruginosa, 6-hourly dosing of 4.5 g
piperacillin-tazobactam is unlikely to provide sufficient
piperacillin exposure when the CLCR is ≥90 ml/min.
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